Development of a secretable frataxin for Friedrich’s ataxia with Dr. Dan DuBreuil
Failed to add items
Sorry, we are unable to add the item because your shopping cart is already at capacity.
Add to basket failed.
Please try again later
Add to wishlist failed.
Please try again later
Remove from wishlist failed.
Please try again later
Adding to library failed
Please try again
Follow podcast failed
Unfollow podcast failed
Development of a secretable frataxin for Friedrich’s ataxia with Dr. Dan DuBreuil
-
Narrated by:
-
By:
In this episode, recorded on-site at the ASGCT 2026 Annual Meeting, Molecular Therapy Advances Associate Editor-in-Chief Dr. Dan Stone speaks with Dr. Dan DuBreuil of Sanofi. They break down the science behind a recent paper detailing the development of a secretable frataxin, highlighting its potential to improve treatment efficacy for Friedreich’s ataxia.
Music: 'Electric Dreams' by Scott Buckley - released under CC-BY 4.0. www.scottbuckley.com.au
Show your support for ASGCT!: https://asgct.org/membership/donate
See omnystudio.com/listener for privacy information.
adbl_web_anon_alc_button_suppression_t1
No reviews yet